MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

53.91
+0.82
+1.54%
Opening 11:12 08/14 EDT
OPEN
52.89
PREV CLOSE
53.09
HIGH
54.00
LOW
52.79
VOLUME
113.11K
TURNOVER
--
52 WEEK HIGH
73.09
52 WEEK LOW
39.32
MARKET CAP
7.53B
P/E (TTM)
60.07
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IONS stock price target is 68.11 with a high estimate of 120.00 and a low estimate of 19.00.

EPS

IONS News

More
Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $78
Citigroup maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $78.
Benzinga · 4d ago
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
Zacks · 08/06 14:21
Ionis Pharmaceuticals EPS beats by $0.34, misses on revenue
Ionis Pharmaceuticals (NASDAQ:IONS): Q2 Non-GAAP EPS of $0.06 beats by $0.34; GAAP EPS of -$0.23 beats by $0.03. Revenue of $146M (-11.0% Y/Y) misses by $2
seekingalpha · 08/05 16:04
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 12:55
Ionis Pharmaceuticals Q2 EPS $(0.23) Beats $(0.27) Estimate, Sales $146.00M Miss $148.87M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 2200 percent decrease over losses of $(0.01) per share
Benzinga · 08/05 11:50
Ionis Pharmaceuticals Q2 EPS $(0.23) Beats $(0.27) Estimate, Sales $146.00M Miss $148.87M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 2200 percent decrease over losses of $(0.01) per share
Benzinga · 08/05 11:50
Ionis reports second quarter 2020 financial results and recent business achievements
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2020 and recent business highlights.
PR Newswire · 08/05 11:00
Ionis Pharmaceuticals Q2 2020 Earnings Preview
Ionis Pharmaceuticals (NASDAQ:IONS) is scheduled to announce Q2 earnings results on Wednesday, August 5th, before market open. The consensus EPS Estimate i
seekingalpha · 08/04 21:29

Industry

Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
-0.02%

Hot Stocks

Symbol
Price
%Change

About IONS

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
More

Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.